Presence of Genetic Variants Among Young Men With Severe COVID-19.

Importance Severe coronavirus disease 2019 (COVID-19) can occur in younger, predominantly male, patients without preexisting medical conditions. Some individuals may have primary immunodeficiencies that predispose to severe infections caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Objective To explore the presence of genetic variants associated with primary immunodeficiencies among young patients with COVID-19. Design, Setting, and Participants Case series of pairs of brothers without medical history meeting the selection criteria of young (age <35 years) brother pairs admitted to the intensive care unit (ICU) due to severe COVID-19. Four men from 2 unrelated families were admitted to the ICUs of 4 hospitals in the Netherlands between March 23 and April 12, 2020. The final date of follow-up was May 16, 2020. Available family members were included for genetic variant segregation analysis and as controls for functional experiments. Exposure Severe COVID-19. Main Outcome and Measures Results of rapid clinical whole-exome sequencing, performed to identify a potential monogenic cause. Subsequently, basic genetic and immunological tests were performed in primary immune cells isolated from the patients and family members to characterize any immune defects. Results The 4 male patients had a mean age of 26 years (range, 21-32), with no history of major chronic disease. They were previously well before developing respiratory insufficiency due to severe COVID-19, requiring mechanical ventilation in the ICU. The mean duration of ventilatory support was 10 days (range, 9-11); the mean duration of ICU stay was 13 days (range, 10-16). One patient died. Rapid clinical whole-exome sequencing of the patients and segregation in available family members identified loss-of-function variants of the X-chromosomal TLR7. In members of family 1, a maternally inherited 4-nucleotide deletion was identified (c.2129_2132del; p.[Gln710Argfs*18]); the affected members of family 2 carried a missense variant (c.2383G>T; p.[Val795Phe]). In primary peripheral blood mononuclear cells from the patients, downstream type I interferon (IFN) signaling was transcriptionally downregulated, as measured by significantly decreased mRNA expression of IRF7, IFNB1, and ISG15 on stimulation with the TLR7 agonist imiquimod as compared with family members and controls. The production of IFN-γ, a type II IFN, was decreased in patients in response to stimulation with imiquimod. Conclusions and Relevance In this case series of 4 young male patients with severe COVID-19, rare putative loss-of-function variants of X-chromosomal TLR7 were identified that were associated with impaired type I and II IFN responses. These preliminary findings provide insights into the pathogenesis of COVID-19.

[1]  Nicolas Carlier,et al.  Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients , 2020, Science.

[2]  Michael Klompas,et al.  Airborne Transmission of SARS-CoV-2: Theoretical Considerations and Available Evidence. , 2020, JAMA.

[3]  J. Izopet,et al.  TLR7 dosage polymorphism shapes interferogenesis and HIV-1 acute viremia in women. , 2020, JCI insight.

[4]  J. Erdmann,et al.  Genomewide Association Study of Severe Covid-19 with Respiratory Failure , 2020, The New England journal of medicine.

[5]  Manfred S. Green,et al.  The male excess in case-fatality rates for COVID-19. A meta-analytic study of the age-related differences and consistency over six countries , 2020, medRxiv.

[6]  S. Klein,et al.  Considering how biological sex impacts immune responses and COVID-19 outcomes , 2020, Nature Reviews Immunology.

[7]  D. Acharya,et al.  Dysregulation of type I interferon responses in COVID-19 , 2020, Nature Reviews Immunology.

[8]  R. Schwartz,et al.  Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19 , 2020, Cell.

[9]  Kwok-Hung Chan,et al.  Triple combination of interferon beta-1b, lopinavir–ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial , 2020, The Lancet.

[10]  Ryan L. Collins,et al.  The mutational constraint spectrum quantified from variation in 141,456 humans , 2020, Nature.

[11]  M. Moreno-Eutimio,et al.  Bioinformatic analysis and identification of single-stranded RNA sequences recognized by TLR7/8 in the SARS-CoV-2, SARS-CoV, and MERS-CoV genomes , 2020, Microbes and Infection.

[12]  M. Tay,et al.  The trinity of COVID-19: immunity, inflammation and intervention , 2020, Nature Reviews Immunology.

[13]  L. Vissers,et al.  Rapid whole exome sequencing in pregnancies to identify the underlying genetic cause in fetuses with congenital anomalies detected by ultrasound imaging , 2020, Prenatal diagnosis.

[14]  Eun Ji Kim,et al.  Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area. , 2020, JAMA.

[15]  L. Piemonti,et al.  Gender and Age Effects on the Rates of Infection and Deaths in Individuals with Confirmed SARS-CoV-2 Infection in Six European Countries , 2020 .

[16]  S. Merler,et al.  Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region, Italy. , 2020, JAMA.

[17]  C. Eastin,et al.  Clinical Characteristics of Coronavirus Disease 2019 in China , 2020, The Journal of Emergency Medicine.

[18]  J. Casanova,et al.  Human Inborn Errors of Immunity: 2019 Update of the IUIS Phenotypical Classification , 2020, Journal of Clinical Immunology.

[19]  Patrick J. Short,et al.  Integrating healthcare and research genetic data empowers the discovery of 49 novel developmental disorders , 2019, bioRxiv.

[20]  David K. Meyerholz,et al.  IFN-I response timing relative to virus replication determines MERS coronavirus infection outcomes. , 2019, The Journal of clinical investigation.

[21]  J. Schuurs-Hoeijmakers,et al.  Exome sequencing in routine diagnostics: a generic test for 254 patients with primary immunodeficiencies , 2019, Genome Medicine.

[22]  D. Brooks,et al.  Intranasal and epicutaneous administration of Toll-like receptor 7 (TLR7) agonists provides protection against influenza A virus-induced morbidity in mice , 2019, Scientific Reports.

[23]  J. E. Mejía,et al.  Female predisposition to TLR7-driven autoimmunity: gene dosage and the escape from X chromosome inactivation , 2018, Seminars in Immunopathology.

[24]  M. Ait-goughoulte,et al.  TLR7 polymorphism, sex and chronic HBV infection influence plasmacytoid DC maturation by TLR7 ligands , 2018, Antiviral research.

[25]  A. Canivet,et al.  TLR7 escapes X chromosome inactivation in immune cells , 2018, Science Immunology.

[26]  J. Casanova,et al.  Human genetics of infectious diseases: Unique insights into immunological redundancy. , 2017, Seminars in immunology.

[27]  C. Halldén,et al.  Genetic variation of the Toll-like receptors in a Swedish allergic rhinitis case population , 2017, BMC Medical Genetics.

[28]  R. Xavier,et al.  Functional and Genomic Architecture of Borrelia burgdorferi-Induced Cytokine Responses in Humans. , 2016, Cell host & microbe.

[29]  L. Vissers,et al.  Meta-analysis of 2,104 trios provides support for 10 new genes for intellectual disability , 2016, Nature Neuroscience.

[30]  D. Falzarano,et al.  SARS and MERS: recent insights into emerging coronaviruses , 2016, Nature Reviews Microbiology.

[31]  James Y. Zou Analysis of protein-coding genetic variation in 60,706 humans , 2015, Nature.

[32]  Jeung-Hoon Lee,et al.  Roles of TLR7 in Activation of NF-κB Signaling of Keratinocytes by Imiquimod , 2013, PloS one.

[33]  M. Przeworski,et al.  Different selective pressures shape the evolution of Toll-like receptors in human and African great ape populations. , 2013, Human molecular genetics.

[34]  J. Casanova,et al.  Human TLRs and IL-1Rs in host defense: natural insights from evolutionary, epidemiological, and clinical genetics. , 2011, Annual review of immunology.

[35]  Christian Gilissen,et al.  De novo mutations of SETBP1 cause Schinzel-Giedion syndrome , 2010, Nature Genetics.

[36]  M. Altfeld,et al.  Sex differences in the Toll-like receptor–mediated response of plasmacytoid dendritic cells to HIV-1 , 2009, Nature Medicine.

[37]  H. Jessen,et al.  A frequent functional toll-like receptor 7 polymorphism is associated with accelerated HIV-1 disease progression , 2009, AIDS.

[38]  A. Smahi,et al.  TLR3 Deficiency in Patients with Herpes Simplex Encephalitis , 2007, Science.

[39]  S. Akira,et al.  Control of coronavirus infection through plasmacytoid dendritic-cell–derived type I interferon , 2007, Blood.

[40]  J. Casanova,et al.  Herpes Simplex Virus Encephalitis in Human UNC-93B Deficiency , 2006, Science.